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Abstract
Background: Distinguishing urothelial carcinoma (UC) from prostate carcinoma (PC) is important due to potential
therapeutic and prognostic implications. However, this can be a diagnostic challenge when there is limited tissue
and in poorly differentiated tumors. We evaluated the diagnostic utility of a dual immunohistochemical stain
comprising p63 and P501S (prostein), applied sequentially on a single slide and visualized by double chromogen
reaction, in differentiating these two cancers. Thus far, there have been no previous studies assessing the
diagnostic utility of p63 and P501S combined together as a dual immunostain in distinguishing between these
two cancers.
Methods: p63/P501S dual-color sequential immunohistochemical staining was performed on archival material from
132 patients with high-grade UC and 23 patients with PC, and evaluated for p63 (brown nuclear) and P501S (red
cytoplasmic) expression. Both the staining intensity and percentage of positive tumor cells were assessed.
Results: p63 was positive in 119/132 of UC and negative in PC. P501S was positive in 22/23 of PC and negative in
UC. The p63+/P501S- immunoprofile had 90% sensitivity and 100% specificity for UC. The p63-/P501S+
immunoprofile had 96% sensitivity and 100% specificity for PC.
Conclusion: Our results indicate that double sequential immunohistochemical staining with p63 and P501S is
highly specific and can be a useful tool in distinguishing UC from PC especially when there is limited diagnostic
tissue as it can be performed on a single slide.
Background
Distinction between prostate carcinoma (PC) and
urothelial carcinoma (UC) is important due to the
potential therapeutic and prognostic implications.
Whereas hormone therapy may be used in treatment of
PC, chemotherapy is used for UC. However, discrimi-
nating between these two cancers can be a diagnostic
challenge especially in high grade tumors and in the
presence of limited tissue. Immunohistochemistry, using
both established and newer markers, is often used as a
diagnostic tool in identifying the prostatic or urothelial
origin of tumors.
Among the markers used to distinguish between
urothelial and prostate cancers, prostate-specific antigen
(PSA) and prostate-specific acid phosphatase (PSAP) are
most commonly used to establish the prostatic origin of
tumors; however, their expression is significantly
decreased in poorly differentiated prostatic cancers [1,2].
Among the newer markers, prostate-specific membrane
antigen (PSMA) and P501S (prostein) have been shown
to have excellent specificity in differentiating prostate
from urothelial cancers [3]. While alpha-methylacyl-
CoA-racemase (AMACR), also known as P504S, is a
useful biomarker of prostate cancer, it is also expressed
in some non-prostate cancers including urothelial can-
cers [4] and therefore is not useful in making the dis-
tinction between PC and UC. Prostein is a prostate-
specific 553 amino acid protein that was identified by
cDNA subtraction in conjunction with high throughput
microarray screening. It localizes to the cytoplasm, spe-
cifically to the Golgi complex, and its expression is
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grade [5,6].
To establish urothelial differentiation, high molecular
weight cytokeratin (HMWCK, clone 34bE12), thrombo-
modulin, cytokeratin (CK) 7 and CK 20 are commonly
used in clinical practice. However, they often have to be
used as part of an antibody panel and are not specific
for UC [7,8]. Among other markers of urothelial origin
are thrombomodulin, a transmembrane glycoprotein
involved in intravascular coagulation, and uroplakin III,
a transmembrane protein expressed in urothelial cells.
While thrombomodulin is a sensitive urothelial marker,
it is also expressed in a variety of other tumors [9]. Uro-
plakin III is highly specific, but only moderately sensitive
in identifying UC [8,10]. More recently p63 has emerged
as a marker of urothelial differentiation [7,11]. p63 is a
transcription factor belonging to the p53 family that
localizes to the nucleus and shares structural and
sequence homology with p53, and has been shown in
several studies to be a marker of urothelial origin of
tumors [11-13].
The aim of this study was to evaluate the diagnostic
utility of p63 and P501S in distinguishing between PC
and UC using dual-color immunohistochemical staining
performed on a single slide by sequentially applying the
antibodies.
Methods
Cases
Our study was approved by the Institutional Review
Board at the University of Pittsburgh. Archival material
from 139 patients with high grade UC and 25 cases with
PC from the Pathology Department at the University of
Pittsburgh Medical Center (UPMC) was used in this
study. The UC cases consisted of 132 high grade inva-
sive UCs and 7 high grade noninvasive UCs from radical
cystectomy, radical cystoprostatectomy, or transurethral
bladder resections performed at UPMC between 1992
and 2008. Routine formalin-fixed paraffin-embedded
(FFPE) whole sections were used in 23 UC cases, and
the remaining 116 cases were distributed on two tissue
microarrays (TMAs). The TMAs were constructed using
a manual arrayer (Beecher Instruments Inc., San Prairie,
WI). Two to 4 cores (core diameter 0.6 mm) were
represented from each urothelial cancer case. Cores
from adjacent normal appearing urinary bladder tissue
and other anatomic sites were also included in the
TMAs. However, only the cancer containing cores were
scored for this study. For prostate cancer, we used rou-
tine FFPE whole sections from 25 patients who under-
went radical prostatectomy for PC at UPMC between
2000 and 2007. None of the patients received neoadju-
vant chemotherapy, radiation, or hormone therapy.
Of the 139 urothelial cancer patients, 6 cases on rou-
tine sections were excluded as there was no tumor and
1c a s eo nT M Aw a se x c l u d e da st h e r ew a sn ot u m o r
present in both the cores obtained from this patient,
after immunohistochemical staining. Among the 25
patients with prostate cancer, 2 cases were excluded as
there was no tumor present on the slide after perform-
ing immunohistochemistry. The remaining 132 urothe-
lial cancer cases and 23 prostate cancer cases [Gleason
score 10 (n = 1), Gleason score 9 (n = 6), Gleason score
8 (n = 7), Gleason score 7 (n = 4), Gleason score 6 (n =
5) were included in the final analyses.
Immunohistochemistry
Immunohistochemistry was performed on 5 micrometer
sections of the FFPE routine sections and TMAs using
monoclonal mouse antibodies against p63 (4A4, DAKO,
Carpinteria, CA) and p501S (10E3, DAKO, Carpinteria,
CA) applied sequentially. The sections were deparaffi-
nized and hydrated, and heat induced epitope retrieval
was performed using Borg decloaking high pH buffer in
the Biocare decloaking chamber. Endogenous peroxidase
activity was blocked with 3% hydrogen peroxide. The
slides were first incubated with an avidin-biotin kit, fol-
lowed by incubations with the p63 primary antibody
(1:200 dilution) for 45 minutes, streptavidin-horseradish
peroxidase, and Betazoid Diaminobenzidine for color
development. Incubation with Denaturing solution for 5
minutes was done before application of the second pri-
mary antibody. P501S primary antibody (1:400 dilution)
was then applied and incubated for 45 minutes, followed
by incubations with alkaline phosphatase streptavidin,
and Vulcan Fast Red chromogen. The slides were coun-
terstained with Dako Hematoxylin, rinsed with water,
dehydrated with alcohol and xylene, and coverslipped.
Appropriate controls were included. All incubations
were done at room temperature.
Scoring and Evaluation
Immunohistochemical expression was assessed semi-
quantitatively for staining intensity and percentage of
positive tumor cells with brown nuclear staining (for
p63) and red cytoplasmic staining (for P501S). Only
moderate or strong staining in at least 5% of the tumor
cells was considered positive. For the TMAs, a case was
considered positive if at least one core showed positivity.
Immunohistochemical staining scores for p63 and
P501S were individually compared between urothelial
and prostate cancers, and a p-value less than 0.05 was
considered statistically significant. The sensitivity, speci-
ficity, and predictive values for combined p63 and
P501S immunostaining was also determined for both
tumor types.
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The immunohistochemical findings are summarized in
Table 1. Neither UC nor PC was positive for both p63
and p501S. Statistically significant p-values were
observed for p63 and P501S expression, individually, in
the distinction of UC from PC. One hundred nineteen
of 132 (90.2%) UC were positive and none of the PC
were positive for p63 (p < 0.0001). Twenty-two of 23
(95.7%) PC cases were positive and none of the UC
cases were positive for p501S (p < 0.0001). p63 showed
diffuse brown nuclear staining in urothelial cancers. p63
expression was also seen in the basal layer of the benign
prostate glands included in some of the sections and
this served as a positive internal control for p63 staining.
P501S showed red granular perinuclear cytoplasmic
staining of prostate cancer cells. Benign prostatic tissue
included in some of the cases also showed P501S posi-
tivity (Figure 1).
The p63 and P501S combination immunohistochem-
ical profiles in UC and PC are illustrated in Figure 2.
The sensitivity, specificity, and predictive values of p63
and P501S combination immunoprofiles for
distinguishing PC from UC are shown in Table 2. The
p63+/p501S- immunohistochemical profile was seen
only in UCs (90.2% sensitivity, 100% specificity, and
100% positive predictive value) and the p63-/p501S+
imunohistochemical profile was seen only in PCs (95.7%
sensitivity, 100% specificity, and 100% positive predictive
value).
Discussion
Morphological distinction of UC from PC can often be a
diagnostic challenge especially in poorly differentiated
tumors. Additionally, serum PSA levels may be raised in
urothelial cancers that infiltrate the prostate gland adding
to the diagnostic dilemma. Immunohistochemistry is
often used as a diagnostic tool to accurately distinguish
between these two tumors and establish the final diagno-
sis [14]. The difficulty in making an accurate distinction
is further compounded when there is only limited tissue
available, such as in needle biopsies, cell blocks and fine
needle aspirations with only small foci of carcinoma,
when additional sections may have to be ordered and
t h e r em a yn o tb ea d e q u a t et i s s u er e m a i n i n gt op e r f o r m
multiple immunohistochemical stains on separate slides.
Although the diagnostic utility of p63 and P501S in
distinguishing between primary PC and UC have been
individually evaluated previously [3,11,15], thus far,
there have been no previous studies evaluating these
two markers together either as a cocktail or applied
sequentially. Our results indicate that dual-color immu-
nohistochemistry with p63 and P501S applied
Table 1 Immunohistochemical expression of p63 and
P501S in urothelial carcinoma (UC) and prostate
carcinoma (PC)
Immunohistochemical stain UC, n = 132 (%) PC, n = 23 (%)
p63 119/132 (90.2) 0/23 (0)
p501S 0/132 (0) 22/23 (95.7)
Figure 1 Dual p63/P501S immunohistochemical stain. A. Benign prostate glands with foci of basal cell hyperplasia showing red granular
perinuclear cytoplasmic P501S staining and diffuse brown nuclear p63 staining of basal cell layer (X200.); B. Prostate cancer with red perinuclear
cytoplasmic P501S staining and no brown nuclear p63 staining (X400); C. Urothelial carcinoma with diffuse brown nuclear p63 staining and
absence of red P501S staining (X400).
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UC from PC. The differential localization (diffuse
nuclear for p63 versus granular cytoplasmic for P501S)
combined with the double chromogen reaction facilitate
easy visualization (brown for p63 and red for P501S)
and enable quick and easy interpretation of the markers
all in one slide. Additionally, this technique can be easily
performed in the laboratory and conserves tissue as it is
performed on a single slide. Thus, this immunostain
could be a potentially valuable tool to aid in the distinc-
tion between these two cancers in the presence of lim-
ited tissue. However, in order to accurately characterize
this double sequential immunostain, further studies
comparing its performance with immunohistochemistry
performed using the same antibodies individually as well
as comparing its performance in prostate needle biopsies
versus radical prostatectomies are required.
In the current study, p63 positivity was seen in 119/
132 (90%) of UC cases. None of the PCs were positive
for p63. Of the 13 UC cases that were negative for p63,
3 cases had micropapillary features. Our results are
comparable to Kunju et al [15] who also found diffuse
nuclear p63 positivity in 92% of their UC cases using
the same p63 monoclonal antibody. Chuang et al [3]
using the same p63 antibody found p63 in 83% of their
UC cases. Similar to our study, Kunju et al and Chuang
et al did not observe nuclear p63 positivity in any of
their PCs. Thus, p63 appears to be a useful marker in
distinguishing between UC and PC due to its high speci-
ficity for UC.
We found granular perinuclear cytoplasmic P501S
expression in 22/23 (96%) PC cases. There was no dif-
ference in P501S staining intensity across PC cases
according to Gleason scores. None of the UCs in our
study showed P501S positivity. Our results are similar to
Kalos et al [5] who found prostein expression in 111/
118 (94%) primary and metastatic prostate cancers.
They also found prostein to have excellent specificity
with no expression detected in 4,635 normal and malig-
nant non-prostatic tissues. Chuang et al observed P501S
positivity in all of their 38 PC cases. These authors also
found P501S to have high specificity with only 2/35
(6%) high grade UC showing focal weak positivity.
Other studies [16,17] have also shown prostein expres-
sion to be a highly specific marker for identification of
prostatic origin of tumors. The granular perinuclear
cytoplasmic expression of prostein is an important fea-
ture in establishing the prostatic origin of tumors. A
recent study by Lane et al [18] found moderate diffuse
cytoplasmic P501S staining in 11% of urinary bladder
adenocarcinomas.
The single P501S negative case in our study was diag-
nosed as a poorly differentiated prostatic adenocarci-
noma (Gleason score 9). The focus of carcinoma seen
Figure 2 p63/P501S combination immunohistochemical profile in urothelial carcinoma (UC) and prostate carcinoma (PC).
Table 2 Sensitivity, specificity, and predictive values: p63/p501S immunostaining in urothelial carcinoma (UC) and
prostate carcinoma (PC)
Immunohistochemical profile Sensitivity Specificity Positive predictive value Negative predictive value
P63+/p501S- for UC 90.2% 100% 1 0.639
P63-/P501S+ for PC 95.7% 100% 1 0.992
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features and p63 negativity for basal cells. Although
prostein expression was absent in this focus of carci-
noma, adjacent areas of high-grade prostatic intrae-
pithelial neoplasias (HGPIN) expressed prostein and
also showed p63 reactivity in the basal cells. It has
been previously described that the expression of
AMACR, is absent or decreased in atrophic PCs [19].
It is possible that prostein expression may similarly be
decreased in prostate cancer with atrophic features.
This could lead to a potential diagnostic pitfall espe-
cially in rare cases of prostate cancer when p63 is
aberrantly expressed in a non-basal distribution [20].
Due to the potential impact on clinical practice,
further studies are required to validate our finding and
determine if prostein immunoreactivity varies among
specific morphological variants of PC.
Our findings indicate that p63/P501S dual immunos-
taining shows excellent specificity and good sensitivity
in distinguishing urothelial from PC. A p63+/P501S-
immunoprofile favors a diagnosis of UC with 90.2% sen-
sitivity and 100% specificity, while a p63-/P501S+ profile
establishes a diagnosis of PC with 95.7% sensitivity and
100% specificity. The p63-/P501S- profile was seen in 14
cases (9%), 13 of which were urothelial cancers. Caution
should be exercised in interpreting a p63-/P501S- profile
as lack of p63expression does not rule out UC. Kunju et
al [15] using a panel comprising PSA, HMWCK, and
p63 to distinguish between PC and UC in 26 diagnosti-
cally challenging cases found p63 positivity in 10/13
UCs. The 3 remaining p63 negative UCs were also nega-
tive for HMWCK, and they established the urothelial
origin using CK 7 and CK 20 expression. In a study by
Higgins et al [11] that included 321 bladder UCs (n =
238 high grade, n = 83 low grade) and 267 PCs, placen-
tal S100 (S100P) and GATA 3 emerged as markers asso-
ciated with urothelial differentiation, and S100P was
found to have higher sensitivity for UCs. They found
p 6 3e x p r e s s i o ni n8 7 %o fU C sa n do n l y0 . 4 %o fP C s .
However, when the expression of S100P was also con-
sidered, 94.9% of all UCs expressed one or both mar-
kers, while none of their PCs expressed both p63 and
S100P. Higgins et al concluded that the expression of
S100P and p63 are partly complementary and when
used in combination each marker may identify UC cases
missed by the other. Some studies have shown high sen-
sitivity for detection of UC with HMWCK (clone
34bE12) [21] and thrombomodulin [9]. Immunohisto-
chemistry using a triple antibody combination of p63,
P501S, and S100P or HMWCK or thrombomodulin may
increase the sensitivity of the p63/P501S immunostain
for detection of UC, and needs to be confirmed in
future studies.
Conclusion
In conclusion, our results indicate that double sequential
immunostaining with p63/p501S is highly specific in dis-
tinguishing primary PC from UC, and support the
potential clinical utility of this immunostain as a diag-
nostic tool in distinguishing between these two cancers
in settings where only limited diagnostic material is
available since it enables simultaneous evaluation of
both markers on a single histologic slide. Using a triple
immunostain by adding another sensitive urothelial mar-
ker may further improve the diagnostic performance of
this immunostain.
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